Travere Therapeutics Inc at William Blair Growth Stock Conference Transcript
Good afternoon. We'll get started. I hope everyone had a great lunch. I preferred the lunch a lot more than usual [years]. This was fantastic. So in case you haven't met me, I'm Tim Lugo, the Head of Biotech Research here at William Blair. It's my pleasure to welcome Chris Cline and Peter Heerma, Chief Commercial Officer and CFO at Travere Therapeutics. And it's a great time for investors to look at Travere. They are in the middle or they're at the beginning of a launch of Filspari in IgAN. We also had some recent data for -- from sparsentan FSGS, which I know Chris and Peter will talk about. So it's my pleasure to welcome both of them to this year's William Blair Growth Stock Conference. And I must remind everyone to look at williamblair.com for all relevant disclosures.
So with that, I'll hand it over to Chris.
All right. Well, thank you very much, Tim and William Blair for hosting us today. It's great to be here. We will be making forward-looking statements. So please
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |